Torsten Danfors
Specialistläkare vid Institutionen för kirurgiska vetenskaper; Molekylär avbildning och medicinsk fysik
- E-post:
- torsten.danfors@uu.se
- Besöksadress:
- Akademiska sjukhuset, ingång 70, 1tr
- Postadress:
- Akademiska sjukhuset, ingång 70, 1tr
751 85 UPPSALA
- Akademiska meriter:
- Med dr ST-läk
Mer information visas för dig som medarbetare om du loggar in.
Publikationer
Senaste publikationer
- Striatal dopamine transporter and receptor availability correlate with relative cerebral blood flow measured with [11C]PE2I, [18F]FE-PE2I and [11C]raclopride PET in healthy individuals (2023)
- The Uppsala APP deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid beta fibril formation (2021)
- Evaluation of Arterial Spin Labeling MRI (2021)
- Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases (2020)
- Phenotypic variability in chorea-acanthocytosis associated with novel VPS13A mutations (2020)
Alla publikationer
Artiklar
- Striatal dopamine transporter and receptor availability correlate with relative cerebral blood flow measured with [11C]PE2I, [18F]FE-PE2I and [11C]raclopride PET in healthy individuals (2023)
- The Uppsala APP deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid beta fibril formation (2021)
- Evaluation of Arterial Spin Labeling MRI (2021)
- Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases (2020)
- Phenotypic variability in chorea-acanthocytosis associated with novel VPS13A mutations (2020)
- Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity (2019)
- Z-score maps from low-dose 18F-FDG PET of the brain in neurodegenerative dementia. (2018)
- Blood Flow Dependence of Early [C-11]PE2I and [F-18]FE-PE2I PET SUVR Measurements Used In the Differential Diagnosis of Parkinsonian Disorders (2018)
- Flutemetamol and FDG Brain-PET Image Reconstruction Methods Affect Software-Aided Diagnosis in Patients with Neurodegenerative Diseases (2018)
- Evaluation of penalized likelihood estimation reconstruction on a digital time-of-flight PET/CT scanner for 18F-FDG whole-body examinations (2018)
- Differential diagnosis of patients with parkinsonian syndrome using multilinear regression to disease-specific C-11-PE2I-PET templates and classification tree learning (2018)
- Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. (2017)
- Development of a clinically feasible [11C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction. (2017)
- Optimisation of penalized likelihood estimation reconstruction (Q.Clear) on a digital time-of-flight PET-CT scanner for four different PET tracers (2017)
- Tracer kinetic analysis of the SV2A ligand 11C-UCBA as a PET marker for synaptic density in humans (2017)
- Quantitative assessment of synaptic density using the SV2A ligand C-11-UCBA in humans (2017)
- The role of methionine positron emission tomography in the evaluation of central nervous system tumors in children (2016)
- Validation of true low-dose 18F-FDG PET of the brain (2016)
- Validation of true low-dose 18F-FDG PET of the brain (2016)
- Visual Assessment of Brain Perfusion MRI Scans in Dementia (2016)
- Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography (2016)
- Validation of Zero-Echo Time PET-MR against stand-alone PET using dynamic dopamine transporter imaging (2016)
- Use of C-11-PE2I PET in Differential Diagnosis of Parkinsonian Disorders (2015)
- Seizure outcomes in relation to the extent of resection of the perifocal fluorodeoxyglucose and flumazenil PET abnormalities in anteromedial temporal lobectomy (2015)
- Differential diagnosis of therapy-related changes and recurrent intracranial tumours using perfusion MRI and methionine PET (2014)
- Validation of parametric methods for [(11)C]PE2I positron emission tomography (2013)
- Relative Cerbral Blood Flow Measurement using dynamic Flumazenil-PET may Replace Fluorodeoxyglucose-PET in Epilepsy Surgical Investigations (2012)
- Parametric methods for [11C]PE2I positron emission tomography (2012)
- PET response and tumor stabilization under erlotinib and bevacizumab treatment of an intracranial lesion non-invasively diagnosed as likely chordoma (2011)
- Increased neurokinin-1 receptor availability in temporal lobe epilepsy (2011)
- Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure (2010)
- Epileptic seizures and survival in early disease of grade 2 gliomas (2009)
- Tetrahydrobiopterin in the treatment of children with autistic disorder. A double-blind placebo-controlled crossover study (2005)
- 11C-autoradiographic studies of dynamic changes in glial cells and benzodiazepine receptor binding in a model of posttraumatic epilepsy
- The Uppsala APP deletion causes early onset autosomal dominant Alzheimer’s disease by altering APP processing and increasing amyloid-β fibril formation
- Biological markers for CNS damage in a patient cohort with suspected autoimmune psychiatric disease
- Cerebral blood flow in multiple sclerosis: an 15O-water PET study